In a small, investigator-initiated Phase II study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable ...

Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

Elevated levels of the protein, also referred to as Gal3, has also been associated with worse outcomes for patients with uterine serous cancer — a more aggressive type of uterine cancer, which affects ...

Epidemiological profile of Ophir Loyola Cancer Hospital: A snapshot of the incidence of solid neoplasms in the eastern Amazon. Patterns and trends in incidence, survival, and treatment among patients ...

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed ...

Add Yahoo as a preferred source to see more of our stories on Google. When you think of the most common gynecological cancer, you probably don’t think of uterine cancer, but this cancer type is more ...

A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer. This is an ASCO Meeting Abstract from the ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ursula A.